中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2012年
12期
1000-1003
,共4页
钟国成%颜斌%孙薏%张小玉%陈健%苏毅%孙浩平%龙海霞%朱波
鐘國成%顏斌%孫薏%張小玉%陳健%囌毅%孫浩平%龍海霞%硃波
종국성%안빈%손의%장소옥%진건%소의%손호평%룡해하%주파
多发性骨髓瘤%免疫疗法%树突细胞%杀伤细胞
多髮性骨髓瘤%免疫療法%樹突細胞%殺傷細胞
다발성골수류%면역요법%수돌세포%살상세포
Multiple myeloma%Immunotherapy%Dendritic cells%Killer cells
目的 研究树突细胞(DC)与细胞因子诱导的杀伤细胞(CIK)为效应细胞的过继免疫联合化疗治疗多发性骨髓瘤(MM)患者的免疫机制和临床疗效.方法 将60例MM患者随机分为2组:化疗组30例,给予适合的化疗方案;联合组30例,除接受适合的化疗外,还给予DC-CIK免疫治疗.记录所有患者在化疗前后的免疫学指标,并比较治疗后两组患者的临床疗效.结果 化疗后,所有患者的免疫指标[热休克蛋白70表达水平为(20.87±4.79) μg/L;Th1/Th2比值为1.39±0.31;转移生长因子-β表达水平为(0.97±0.32 )μg/L;CD4+CD25+细胞百分比为(8.26±2.18)%]与化疗前[(18.24±4.16)μg/L、1.22±0.25、(1.19±0.46)μg/L、(10.31±2.54)%]比较,差异均有统计学意义(P值均<0.05);治疗后,联合组患者的生活质量和临床疗效[PS评分为2.26±0.41;瘤细胞百分比为(24.73±6.38)%;β2微球蛋白表达水平为(7.14±2.03)mg/L;24 h尿液轻链为(11.26±3.67)mg;肌酐水平为(162.40±33.84)μmol/L]与化疗组患者[2.57±0.58;(29.12±8.67)%;(9.35±3.42)mg/L;(14.78±4.23)mg;(187.50±46.53)μmol/L]比较,均有所提高(P值均<0.05).结论 化疗能减轻MM患者肿瘤细胞的免疫抑制,促进DC-CIK的抗瘤活性;DC-CIK免疫治疗与化疗联合应用于MM患者具有良好的协同疗效.
目的 研究樹突細胞(DC)與細胞因子誘導的殺傷細胞(CIK)為效應細胞的過繼免疫聯閤化療治療多髮性骨髓瘤(MM)患者的免疫機製和臨床療效.方法 將60例MM患者隨機分為2組:化療組30例,給予適閤的化療方案;聯閤組30例,除接受適閤的化療外,還給予DC-CIK免疫治療.記錄所有患者在化療前後的免疫學指標,併比較治療後兩組患者的臨床療效.結果 化療後,所有患者的免疫指標[熱休剋蛋白70錶達水平為(20.87±4.79) μg/L;Th1/Th2比值為1.39±0.31;轉移生長因子-β錶達水平為(0.97±0.32 )μg/L;CD4+CD25+細胞百分比為(8.26±2.18)%]與化療前[(18.24±4.16)μg/L、1.22±0.25、(1.19±0.46)μg/L、(10.31±2.54)%]比較,差異均有統計學意義(P值均<0.05);治療後,聯閤組患者的生活質量和臨床療效[PS評分為2.26±0.41;瘤細胞百分比為(24.73±6.38)%;β2微毬蛋白錶達水平為(7.14±2.03)mg/L;24 h尿液輕鏈為(11.26±3.67)mg;肌酐水平為(162.40±33.84)μmol/L]與化療組患者[2.57±0.58;(29.12±8.67)%;(9.35±3.42)mg/L;(14.78±4.23)mg;(187.50±46.53)μmol/L]比較,均有所提高(P值均<0.05).結論 化療能減輕MM患者腫瘤細胞的免疫抑製,促進DC-CIK的抗瘤活性;DC-CIK免疫治療與化療聯閤應用于MM患者具有良好的協同療效.
목적 연구수돌세포(DC)여세포인자유도적살상세포(CIK)위효응세포적과계면역연합화료치료다발성골수류(MM)환자적면역궤제화림상료효.방법 장60례MM환자수궤분위2조:화료조30례,급여괄합적화료방안;연합조30례,제접수괄합적화료외,환급여DC-CIK면역치료.기록소유환자재화료전후적면역학지표,병비교치료후량조환자적림상료효.결과 화료후,소유환자적면역지표[열휴극단백70표체수평위(20.87±4.79) μg/L;Th1/Th2비치위1.39±0.31;전이생장인자-β표체수평위(0.97±0.32 )μg/L;CD4+CD25+세포백분비위(8.26±2.18)%]여화료전[(18.24±4.16)μg/L、1.22±0.25、(1.19±0.46)μg/L、(10.31±2.54)%]비교,차이균유통계학의의(P치균<0.05);치료후,연합조환자적생활질량화림상료효[PS평분위2.26±0.41;류세포백분비위(24.73±6.38)%;β2미구단백표체수평위(7.14±2.03)mg/L;24 h뇨액경련위(11.26±3.67)mg;기항수평위(162.40±33.84)μmol/L]여화료조환자[2.57±0.58;(29.12±8.67)%;(9.35±3.42)mg/L;(14.78±4.23)mg;(187.50±46.53)μmol/L]비교,균유소제고(P치균<0.05).결론 화료능감경MM환자종류세포적면역억제,촉진DC-CIK적항류활성;DC-CIK면역치료여화료연합응용우MM환자구유량호적협동료효.
Objective This research was aimed to evaluate the immune mechanism and clinical effect of immunotherapy of dendritic cells (DC) and cytokine-induced killer cell (CIK) combined with chemotherapy on multiple myeloma (MM). Methods 60 patients with MM were randomly divided into two groups. 30 patients in chemotherapy group were treated by chemotherapy only, 30 patients in joint group were treated by adoptive immunotherapy (DC-CIK) combined with chemotherapy. A variety of immunological indexes (Hsp70,Th1/Th2,TGF-β) of all patients before and after chemotherapy were recorded; Also the clinical outcomes between two groups were compared. Results After chemotherapy, the immunological indexes of all patients were better than those of before chemotherapy (P<0.05); After treatment, quality of life, clinical index and survival in joint group were better than in chemotherapy group (P<0.05). Conclusion Chemotherapy could break the immunosuppression of MM and improve the anti-tumor response of DC-CIK; Chemotherapy and DC-CIK may have synergistic effect for MM.
